



SINCLAIR PHARMA ANNOUNCES NEW PRODUCT T-GO™ AND ITS EU REGISTRATION

Godalming, UK, 7 July 2004: Sinclair Pharma plc ("Sinclair" or the "Company"), the pharmaceutical company focused on the acquisition, development and out-licensing of niche patented products, today announces the receipt of EU regulatory approval as a medical device for a new patented product, T-GO™, a treatment for painful throat conditions such as pharyngitis. T-Go™, which uses the Aloclair™ platform technology, is presented initially in the form of a liquid gargle but is also being developed as a tablet and spray. The registration of T-Go™ as a medical device in the EU is significantly ahead of the Company's expectations.

Sinclair utilised the platform technology from its product Aloclair™ for the pain relief of mouth ulcers and other oral lesions, following feedback from users who found gargling with it helped relieve sore throat symptoms. Having achieved EU registration well ahead of schedule, the Company now believes that the product may be launched early in its next financial year ending June 30th 2006.

The OTC sore throat remedies market in the five major European markets is currently valued at €600m¹; the US and Japanese markets increase this to an estimated total of €1.6bn²

Sinclair Pharma CEO, Dr Michael Flynn, commented: "We are pleased to have another registration ahead of schedule. We believe there is a need for an effective well tolerated remedy for throat pain and that T-Go™ further establishes our portfolio of products to address common afflictions of the mouth and gums. The development of Sinclair's patented technologies is a key strategy for the Company. T-Go™ is the fifth new product to result from one of these platforms. We have now 8 products through to approval in EU and 7 in the US and anticipate significant sales growth as our marketing and distribution network introduces them in the major markets."

ENDS

¹ IMS data 2004

² Exterpolated from IMS figures for five major European markets

Contacts:**Sinclair Pharma plc**

Dr Michael Flynn, CEO

Jerry Randall, CFO

John Barrington-Carver (Media Enquiries)

Tel: +44 (0) 1483 426 644

Tel: +44 (0) 7831 655 630

Financial Dynamics

Ben Atwell

Lucy Briggs

Tel: +44 (0) 207 831 3113

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.

Notes to Editors

Sinclair Pharma plc is an international pharmaceutical company focused on the acquisition and development of niche patented products in the fields of oral health, oncology support and dermatology and brings them to the international market place. The Company combines product evaluation, product development, regulatory and business development expertise to add value to its acquired and in-house developed products. A key element of the Sinclair business model is to minimise risk and exposure by avoiding involvement in lengthy R&D programmes and rapidly achieving global distribution through a network of marketing partners. The Company has already licensed distribution in over 40 countries for the Group's products.

www.sinclairpharma.com